% | $
Quotes you view appear here for quick access.

BioTelemetry, Inc. Message Board

  • chris_cs16 chris_cs16 Dec 4, 2013 1:35 PM Flag

    Lake Street Maintains $14 per share target

    Lake Street feels the decline in reimbursement rates will be made up with growth in other areas, maintains $14 per share target.

    Lake Street said BioTelemetry is likely to have reduced 2014 revenue due to a 13.7% reduction in CMS MCOT reimbursement. The firm has not made any estimate changes as it expects the new contract with Anthem and the INR business to offset the loss. Shares are Buy rated with a $14 price target.

    Seems like a good time to buy on this over-reaction...

    Sentiment: Buy

12.91+0.12(+0.94%)Nov 27 1:00 PMEST